Arix Bioscience takes stake in Aussie fibrosis specialist Pharmaxis
Arix led a A$24mln (£13.4mln) primary placing and will invest A$14.2mln itself in two tranches
Company
Syntara Ltd
ASX:PXS
Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction. This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
175 stories · page 2 of 2
Investments and investor services
FTSE 100 closes higher, supported by gains in oil giants as crude prices rise
At the close, the UK blue chip index was 4.68 points higher at 7,663.78, just below the session peak of 7,681.86, having recovered from a low of 7,636.60
Investments and investor services
Pharmaxis secures $24 million at premium to support partnering negotiations
The capital raising was priced at a premium to the last traded share price.
Pharmaxis enters trading halt ahead of share placement
The company plans to raise funds by way of a share placement.
Pharmaxis powering ahead with phase I LOXL2 studies
The company finished the June quarter with just over $31 million in cash.
Pharmaxis phase I trial attracts interest from multiple pharmaceutical companies
Final stages of phase I studies and phase II enabling toxicity studies are due to complete in Q3 2018.
Pharmaxis boosts cash position securing sustainable future
Large pharma companies are being attracted to the company’s drug development portfolio.
Pharmaxis outlines share price catalysts for 2018
Value inflection points are expected in a number of programs.
Pharmaxis strengthens balance sheet with $15 million milestone payment
The payment has unlocked the full deal potential of $625 million.
Pharmaxis secures further Australian government reimbursement for Bronchitol
Pharmaxis is a global leader in drug development for fibrosis and inflammation.
Archive
Proactive news snapshot: Synairgen, Iofina, Atlantis Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Scancell Holdings soars after "stunning endorsement" of its ImmunoBody platform
Cancer Research UK was immensely impressed with the company and its technology
Synairgen shoots higher on new terms for fibrosis collaboration
Synairgen will retain a 17% interest in any partnership across all fibrotic indications
Pharmaxis takes full control of collaboration on LOXL2 inhibitors and expands scientific program
The program scope has been doubled to encompass two lead candidates.
Pharmaxis boosts its drug discovery ranks
The company has made three new hires including a head of chemistry.
Lots of potential for Synairgen in fibrosis, suggests broker finncap
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
Pharmaxis and collaborator Synairgen advance towards human clinical studies
The Pharmaxis drug discovery group has developed a number of selective small molecule inhibitors.
Pharmaxis' largest shareholder BVF Partners LP lifts stake
The Pharmaxis register contains international specialist biotech investors.
Pharmaxis to receive cash injection as Boehringer Ingelheim initiates new trials
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis.
Pharmaxis receives support for expanded reimbursement of its drug Bronchitol®
Bronchitol® is an inhaled dry powder for the treatment of cystic fibrosis.
Pharmaxis enters new quarter positioned for growth
The company finished the June quarter with $21.5 million in cash and is expecting more milestone payments this year.
Pharmaxis meets primary endpoint of Phase 3 trial of Bronchitol®
Pharmaxis has partnered its work on Bronchitol for the U.S. with Chiesi Group.
Pharmaxis appoints highly-experienced Dr Kathleen Metters to the board
Pharmaxis held a $25.5 million cash balance at the end of March.
Pharmaxis shares close higher on new cash payment
Pharmaxis is an Australian pharmaceutical research company.
Pharmaxis is now expecting a further cash injection
Payments of circa A$42 million are expected this year.
Pharmaxis 'extremely pleased' following supply agreement with Chiesi Farmaceutici SpA
The agreement is for the commercialisation of Bronchitol®.
Pharmaxis approaching three key potential share price drivers
The June quarter will keep investors leveraged to valuable news flow.
Pharmaxis’ substantial shareholders increase stakes
Today and yesterday, two substantial holders have increased their stakes.
Pharmaxis completes treatment phase in clinical trial for U.S. market
Pharmaxis' partner has funded US$22 million of the expected US$26 million trial cost.
Admedus appoints Simon Buckingham to board
Buckingham has more than 25 years’ experience in the global pharmaceutical industry.
Pharmaxis enters 2017 cashed up as shares strengthen
Pharmaxis is becoming a more enticing target for drug acquisition and partnerships.
Pharmaxis on track for multi-million euro milestone payment
The commencement of the trial will trigger a milestone payment.
Pharmaxis chairman buys shares on market
Pharmaxis (ASX:PXS) chairman, Malcolm McComas has acquired 200,000 shares on market for a total cost of $54,167.
Pharmaxis Ltd looking like an enticing target for big pharma
Mergers and acquisitions are increasing in the fibrosis and NASH space.
Pharmaxis Ltd in research collaboration with prestigious institute
Gary Phillips, CEO, commented: "This research will bring together the acknowledged expertise of the Woolcock Institute and Pharmaxis in the field of cystic fibrosis."
Pharmaxis Ltd gets approval to sell Bronchitol® in largest market yet, Russia
Entry into the Russian market for Bronchitol is a significant achievement for the company as it looks to expand the drug’s customer base and increase its potential to generate revenue.
Pharmaxis Ltd stands to gain as NASH biotech acquired for US$1.7B
Market activity in the past has already confirmed that the treatment of NASH is one of the hottest areas in biotech and Allergan’s takeover bid for Tobira has only added fuel to the fire.
Pharmaxis Ltd completes first year of new business plan
Progress under the new business model over the 2016 financial year has been substantial. The company finished the financial year with a cash balance of $39 million and net cash usage over the year of $15 million.
Pharmaxis Ltd achieves milestone as it targets the U.S. market
Gary Phillips, CEO, commented: "We are pleased to have attained this significant milestone in such a large undertaking securing more than 400 study participants at 126 sites in 21 countries."
Pharmaxis Ltd targets big pharma at world's largest biotech conference
BIO is the largest global event for the biotech industry with nearly 16,000 industry leaders from 76 countries attending the conference and over 3,400 companies participating in partnering meetings.
Pharmaxis portfolio fires on all pistons as U.S. relations warm up
Strengthening relationships, a multi-pronged research program and an agenda for milestone payments have Pharmaxis in good shape.
ASX recovers as this medical play keeps shining
The Australian All Ordinaries rebounded today with strong performances from all sections except mining, where price woes continue to cause concern. This medical play added to the momentum for health stocks with another positive showing.
ASX bounces back as this medical play drives forward
The Australian All Ordinaries rebounded 2.3% today to 5,079 points with help from a strongly advancing pharmaceutical researcher.
Pharmaxis enhances outlook for cystic fibrosis treatment
Pharmaxis has received positive trial results for its cystic fibrosis treatment, Bronchitol, setting the company up to expand its marketing of the drug in Europe as a plan to penetrate the U.S. market develops.
Pharmaxis pumps up cash as partnerships and products add value
Pharmaxis Limited more than doubled its cash at bank year-on-year to A$50.3 million at the end of the September quarter as the company realised significant drug trialling and collaborative research milestones.
Pharmaxis Limited drug trials success builds product confidence
The successful clinical trial will enable one of the world’s 20 leading pharmaceutical companies, Boehringer Ingelheim, to proceed with further development of the program. Boehringer Ingelheim, a leader in cardiometabolic and respirat
Pharmaxis, Synairgen collaborate on pulmonary fibrosis treatment
The collaboration with Synairgen could accelerate development of the lung disease treatment while reducing risks on the path to value points. Pharmaxis has executed three deals in six months and is tapping into a rich seam of potential drug